1. Pink Sheet
  2. >>Market Access

Hep C Drug Trends: Cost Driver In 2014, But “Leveling Off” Coming, CMS Actuaries Say

 
• By Laura Helbling

CMS actuaries attribute an increase in health spending in 2014 to the expansion of Medicaid and private health insurance coverage and rapid growth in retail drug spending, particularly for new hep C drugs.

The full picture of the remarkable uptake of the new generation of hepatitis C drugs and the impact of coverage expansions led by the Affordable Care Act on national health spending for 2014 is now clear.

The dual factors of coverage expansion and rapid growth in retail prescription drug spending led to a much faster rate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, home of the Pink Sheet, to focus on AI, business harmonization and long-term growth.

AI And Inertia: The Disruptors Keeping EU Regulators Awake At Night

 
• By Francesca Bruce

Data is “the new oil,” but its use will challenge regulators, while inertia is the biggest disrupter of all for European regulators, according to European Medicines Agency chiefs past and present.

AI In Manufacturing: EU To Revamp GMP Guidance In Light Of Digital Advancements

 
• By Eliza Slawther

Pharma firms are being encouraged to respond to a European Commission consultation on planned updates to its good manufacturing practice standards which reflect the “rapid advancement” of modern technologies, like AI and digital systems, in drug manufacturing.